# Protagonist Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Protagonist Therapeutics, Inc). ## Overview Protagonist Therapeutics is a U.S.-based biopharmaceutical company focused on discovering and developing peptide-based medicines for inflammatory and immunologic diseases, hematology, and metabolic disorders. Its pipeline includes internally discovered programs and partnered assets developed with large pharmaceutical collaborators. ## Products & services • Icotyde™ (icotrokinra), oral IL-23 receptor antagonist • Rusfertide, hepcidin-mimetic peptide for polycythemia vera • PN-881, oral IL-17 peptide antagonist • PN-477, obesity triple agonist peptide • Preclinical discovery platform for peptide therapeutics - **Partnered development programs** (55%) — Licensed and collaboration-based drug candidates advanced with pharmaceutical partners. - **Internal clinical pipeline** (35%) — Company-discovered therapeutic candidates in clinical development across I&I and hematology. - **Discovery research programs** (10%) — Early-stage peptide discovery efforts targeting validated biology in new disease areas. - Icotyde™ (icotrokinra), oral IL-23 receptor antagonist - Rusfertide, hepcidin-mimetic peptide for polycythemia vera - PN-881, oral IL-17 peptide antagonist - PN-477, obesity triple agonist peptide - Preclinical discovery platform for peptide therapeutics ## Customers Protagonist does not sell commercial products directly; its economic counterparties are pharmaceutical partners that license or co-develop its drug candidates. Its end-market is ultimately patients and prescribers in specialty disease areas such as psoriasis and polycythemia vera, but near-term revenue is generated through collaboration agreements, milestones, and development services. - **Pharmaceutical collaboration partners** (primary) — Partners such as JNJ and Takeda fund development, pay milestones, and may commercialize assets. - **Specialty prescribers** (secondary) — Dermatologists, hematologists, and other specialists who would prescribe approved therapies. - **Patients in targeted disease areas** (secondary) — Patients with psoriasis, polycythemia vera, and other immune-mediated or metabolic diseases. - **Payers and reimbursement systems** (secondary) — Insurers and health systems that determine access and uptake for approved specialty drugs. - Pharmaceutical partners that license or co-develop pipeline assets - Large-cap collaborators funding late-stage development and commercialization - Physicians and specialty clinics as future prescribers of approved therapies - Patients with inflammatory, hematologic, and metabolic diseases - Payers and health systems that will influence adoption after approval ## Geography Protagonist is headquartered in the United States and conducts its research and development from a U.S. operating base. Its business is global in commercial reach through partners, with regulatory filings and potential launches in the United States and Europe for partnered programs such as Icotyde. - **United States** (100%) — Company is U.S.-based; no country revenue split disclosed. - Headquartered and operated from the United States - Clinical and discovery work centered in the U.S. - Partner filings include the FDA and EMA for Icotyde - Future commercialization depends on partner launch footprints - Global exposure is driven by partnered drug approvals ## Strategy The company’s strategy is to build value through differentiated peptide therapeutics against biologically validated targets, while using partnerships to extend development and commercialization reach. It also continues to broaden its pipeline across inflammation and immunology, hematology, and metabolic disease to diversify scientific and commercial risk. - **Advance partnered late-stage assets** (short-term) — Partnered programs can convert clinical progress into milestone and royalty economics without building a full commercial organization. - **Broaden the internal pipeline** (medium-term) — Multiple programs reduce dependence on any single asset and create future partnering opportunities. - **Preserve partnering optionality** (medium-term) — Collaboration structures can provide non-dilutive funding and commercialization leverage. - Advance differentiated peptide drugs against validated targets - Use partnerships to fund late-stage development and commercialization - Expand the pipeline beyond core I&I assets - Progress hematology and metabolic programs into the clinic - Create optionality through licensing, milestones, and royalties ## Risks Protagonist is highly dependent on clinical success, regulatory approval, and partner execution, because it has no commercialized products of its own. Its revenue can be volatile due to milestone timing, while development-stage biotech economics also expose it to funding needs, competitive pressure, and regulatory review risk. - **Dependence on clinical development success** [critical] — The company’s value is tied to product candidates that must prove safety and efficacy in trials. - **Regulatory approval risk** [high] — FDA and EMA decisions determine whether partnered and internal assets can reach market. - **Partner concentration and execution risk** [high] — Revenue and commercialization depend on a small number of collaboration partners. - **Capital funding risk** [high] — Ongoing R&D and pre-commercial work require external funding if collaboration cash is insufficient. - **Competitive therapeutic landscape** [medium] — Competing drugs may offer better efficacy, convenience, or pricing in target indications. - Clinical trial failure could eliminate value in key programs - Regulatory delays can slow approvals and milestone receipts - Revenue is milestone-driven and can fluctuate sharply - Partner execution affects launch timing and commercialization - Biotech competition may produce better or cheaper therapies ## Accounting Revenue is recognized mainly from license and collaboration agreements, so timing of milestones, upfront allocations, and performance obligations can materially change quarterly results. Stock-based compensation, deferred revenue, and clinical development cost accruals are also important because this is a development-stage biotech with heavy R&D spending and no product sales. - **License and collaboration revenue recognition** — Can create large quarter-to-quarter swings in revenue - **Deferred revenue** — Affects balance sheet liabilities and future revenue recognition - **Stock-based compensation** — Impacts reported operating loss and comparability - **Clinical trial accruals and estimates** — Can shift expense recognition between periods - License and collaboration revenue depends on milestone timing - Upfront payments are allocated across performance obligations - Deferred revenue can shift as collaboration work is delivered - Stock-based compensation is a meaningful non-cash expense - Clinical trial accruals and estimates affect R&D expense timing --- *Last updated: 2026-04-29T04:49:54.716342+00:00*